iNCOVACC- Intranasal covid-19 Vaccine
- It is developed by Hyderabad- based Bharat Biotech and USbased Washington University.
ABOUT VACCINE:-
- It is the world’s first intranasal vaccine approved for public use.
- It is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein.
- iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised SARS-CoV-2 spike protein.
- Vaccine stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses.
- It is non-invasive, Needle-free.
Benefits of Vaccine-
- Being an intranasal vaccine, BBV154 may produce local antibodies in the upper respiratory tract which may have the potential to reduce infection and transmission.
- It triggers an immune response in the mucosal membrane.
- Thus, it provides local immunity as well as convenience of administering with no need for syringes and trained manpower.
- Low costs and also easy to distribute and administer.
- No need for cold chains with very low temperature for storages.
Syllabus: Prelims + Mains; GS3 – Science and Technology
